Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock
1991; Wiley; Volume: 21; Issue: 6 Linguagem: Inglês
10.1111/j.1365-2362.1991.tb01410.x
ISSN1365-2362
AutoresAlfons Billiau, F Vandekerckhove,
Tópico(s)Inflammation biomarkers and pathways
ResumoEuropean Journal of Clinical InvestigationVolume 21, Issue 6 p. 559-573 Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock A. BILLIAU, Corresponding Author A. BILLIAU Laboratory of Immunobiology, The Rega Institute, University of Leuven, BelgiumA. Billiau, Rega Institute, Minderbroedersstraat 10, B-3000 Leuven, Belgium.Search for more papers by this authorF. VANDEKERCKHOVE, F. VANDEKERCKHOVE Laboratory of Immunobiology, The Rega Institute, University of Leuven, BelgiumSearch for more papers by this author A. BILLIAU, Corresponding Author A. BILLIAU Laboratory of Immunobiology, The Rega Institute, University of Leuven, BelgiumA. Billiau, Rega Institute, Minderbroedersstraat 10, B-3000 Leuven, Belgium.Search for more papers by this authorF. VANDEKERCKHOVE, F. VANDEKERCKHOVE Laboratory of Immunobiology, The Rega Institute, University of Leuven, BelgiumSearch for more papers by this author First published: December 1991 https://doi.org/10.1111/j.1365-2362.1991.tb01410.xCitations: 134Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Schlag G, Redl H, Mediators of sepsis. In: JL Vincent, ed. Update in Intensive Care and Emergency Medicine: Septic Shock. Berlin : Springer-Verlag, 1987; 4: 51–73. 2 Warr TA, Mohan-Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481–9. 3 Brown JM, Grosso MA, Harken AH. Cytokines, sepsis and the surgeon. Surg Gynecol Obstet 1989; 169: 568–75. 4 van Deventer SJ et al. Current developments in the field of sepsis: tumor necrosis factor (cachectin). Ned Tijdschr Geneeesk 1989; 133: 17–19. 5 Morrison DC. Endotoxin and disease. Ann Rev Med 1987; 38: 417–32. 6 Parillo JE. The cardiovascular pathophysiology of sepsis. Ann Rev Med 1989; 40: 469–85. 7 Dijkmans R, Decock B, Heremans H, van Damme J, Billiau A. Interferon-γ is cytotoxic for normal mouse fibroblasts: Enhancement by tumor necrosis factor and interleukin-1. J Lymphokine Res 1989; 8: 25–34. 8 Dijkmans R, van Damme J, Cornette F, Heremans H, Billiau A. Bacterial Lipopolysaccharide potentiates gamma-interferon-induced cytotoxicity for normal mouse and rat embryo fibroblasts. Infection and Immunity 1990; 58: 32–6. 9 Semeraro N. Endotoxins and haemostasis. Acta Clinica Belgica 1976; 31: 377–92. 10 Müller-Berghaus G. In: M Verstraete et al., eds. Thrombosis and Haemostasis. University Press Leuven, 1987: 619–71. 11 Deitch EA. Endotoxin-induced impairment of host defenses. In: E Faist, JL Ninneman, D Green, eds. Immune Consequences of Trauma, Shock and Sepsis. Berlin : Springer-Verlag, 1989: 271–8. 12 Ikejima TC, Dinarello CA, Gill DM, Wolff SM. Induction of human interleukin 1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest 1984; 73: 1312–20. 13 Parsonnet J, Hickman RK, Eardley DD, Pier GB. Induction of human interleukin-1 by toxic shock syndrome toxin-1. J Infect Dis 1985; 151: 514–22. 14 Jupin C, Anderson SD, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factor and γ interferon. J Exp Med 1988; 167: 752–61. 15 Micusan VV, Desrosiers M, Gosselin J, Mercier G, Oth D, Bhatti AR, Heremans H, Billiau A. T-cell stimulation and interferon induction by toxic shock syndrome toxin-1. Rev Inf Dis 1989; 11-S: 305–15. 16 Marrack P, Blackman M, Kushnir E, Kappler J. The toxicity of Staphylococcal enterotoxin B in mice is mediated by T cells. J Exp Med 1990; 171: 455–64. 17 White J, Herman A, Pullen AM, Kappler JW, Marrack P. The V β-specific superantigen Staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 1989; 56: 27–35. 18 Janeway CA Jr, Yagi J, Conrad PJ, Katz M, Joners B, Vroegop S, Buxser S. T-cell responses to Mls and to bacterial proteins that mimic its behavior. Immunol Rev 1989; 107: 61–88. 19 Fleischer B, Schrezenmeier H. T cell stimulation by staphylococcal enetrotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 1988; 167: 1697–707. 20 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–5. 21 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultures of vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533–7. 22 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618–23. 23 Wilson D, de Garavilla L, Kuhn W, Togo J, Burch RM, Steranka LR. D-Arg-(Hyp3-D-Phe7)-bradykinin, a bradykinin antagonist, reduces mortality in a rat model of endotoxic shock. Circulatory Shock 1989; 27: 93–101. 24 Hwang D. Essential fatty acids and the immune response. FASEB J 1989; 3: 2052–61. 25 Dinarello CE. Interleukin-1 and Interleukin-1 anatgonism. Blood 1991; 77: 1627–52. 26 Solari R. Identification and distribution of two forms of the interleukin 1 receptor. Cytokine 1990; 2: 21–8. 27 Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CE. Interleukin-1 induces a shock-like state in rabbits. J Clin Invest 1988; 81: 1162–72. 28 Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin-1 and tumor necrosis factor. J Exp Med 1988; 167: 1708–12. 29 Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333–8. 30 Girardin E, Grau G, Dayer J-M, Roux-Lombard P, J5 Study Group, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319: 397–400. 31 Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchi-mont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975–8. 32 Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Endres S, Lonneman G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Inf Dis 1990; 161: 79–97. 33 van der Meer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc Natl Acad Sci USA 1988; 85: 1620–3. 34 Ozaki Y, Ohashi T, Minami A, Nakamura S-I. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1α. Infection and Immunity 1987; 55: 1436–40. 35 Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550–2. 36 Alexander RH, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029–32. 37 Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338–43. 38 Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunology Today 1989; 10: 370–5. 39 Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587–91. 40 Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595–600. 41 Miossec P, Cavender D. Production of interleukin 1 by human endothelial cells. J Immunol 1986; 136: 2486–91. 42 Stern DM, Bank I, Nawroth PP, Cassimeris J, Kisel W, Fento JW, Dinarello CA, Chess L, Jaffe EA. Self-regulation of procoagulant events on the endothelial cell surface. J Exp Med 1985; 162: 1223–5. 43 Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1362–75. 44 Warner SJC, Auger KR, Libby P. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol 1987; 139: 1911–17. 45 Bevilacqua PP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest 1985; 76: 2003–11. 46 Cavender DE, Edelbaum D. Inhibition of endothelial cell activation induced by tumor necrosis factor or lymphotoxin. J Immunol 1988; 141: 3111–16. 47 Gauldie J, Sauder DN, McAdam KPWJ, Dinarello CA. Purified interleukin-1 (IL-1) from human monocytes stimulates acute-phase protein synthesis by rodent hepatocytes in vitro. Immunology 1987; 60: 203–7. 48 Dinarello CA, Cannon JG, Wolff HA, Bernheim HA, Beutler B, Cerami A, Figari MA, Palladino MA, O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433–50. 49 Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-translational expression of interleukin-1 in U937 cells. J Immunol 1987; 139: 4129–34. 50 Knudsen PJ, Dinarello CA, Strom TB. Prostaglandins inhibit post-transcriptional interleukin-1 synthesis by increasing intracellular cyclic adenosine monophosphate. J Immunol 1984; 137: 3189–94. 51 Arenzana-Seisdedos F, Virelizier JL, Fiers W. Interferons as macrophage activating factor. III. Preferential effects of interferon on the interleukin-1 secretory potential of fresh or aged human monocytes. J Immunol 1985; 134: 2444–8. 52 Haq AU, Rinehart JJ, Maca RD. The effect of gamma interferon on IL-1 secretion of in vitrodifferentiated human macrophages. J Leucocyte Biol 1985; 38: 735–46. 53 Ucla C, Roux-Lombard P, Fey S, Dayer J-M, Mach B. Interferon gamma drastically modifies the regulation of interleukin 1 genes by endotoxin in U937 cells. J Clin Invest 1990; 85: 185–91. 54 Collart MA, Belin D, Vassalli J-D, de Konsodo S, Vassalli P. γ interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes which are controlled by short-lived repressors. J Exp Med 1986; 164: 2113–18. 55 Gerrard TL, Siegel JP, Dyer DR, Zoon KC. Differential effects of interferon-α and interferon-γ on interleukin 1 secretion by monocytes. J Immunol 1987; 138: 2535–40. 56 Ruschen S, Lemm G, Warnatz H. Spontaneous and LPS-stimulated production of intracellular IL-1β by synovial macrophages in rheumatoid arthritis is inhibited by IFN-γ. Clin Exp Immuno 1989; 76: 246–51. 57 Ghezzi P, Dinarello CA. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-γ. J Immunol 1988; 140: 4238–44. 58 Schindler R, Ghezzi P, Dinarello CA. IL-1 induces IL-1. IV. IFN-γ suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J Immunol 1990; 144: 2216–22. 59 Beutler B, Cerami A. The biology of cachectin/TNF—a primary mediator of the host response. Ann Rev Immun 1989; 7: 625–55. 60 Paul N, Ruddle N. Lymphotoxin. Ann Rev Immunol 1989; 6: 407–38. 61 Luettig B, Decker T, Lohmann-Matthes M-L. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J Immunol 1989; 143: 4034–8. 62 Gifford GE, Lohmann-Matthes M-L. The requirement for the continual presence of lipopolysaccharide for the production of tumor necrosis factor by thioglycollate induce peritoneal macrophages. Int J Cancer 1986; 38: 135–7. 63 Ayala A, Perrin MM, Meldrum DR, Ertel W, Chaudry IH. Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine 1990; 2: 170–4. 64 Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice. J Exp Med 1988; 167: 1987–92. 65 Movat HZ, Burrowes CE, Cybulsky MI, Dinarello CE. Acute inflammation and a Shwartzman-like reaction induced by interleukin 1 and tumor necrosis factor: synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol 1987; 129: 463–76. 66 Issekutz AC, Wankowicz Z. Synergy between tumor necrosis factor (TNFα) and interleukin 1 (IL-1) in the induction of polymorphonuclear leukocyte (PMNL) emigration. Fed Proc 1987; 46: 737a. 67 Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 1990; 166: 1390–404. 68 Medcalf RL, Kruithof KO, Schleuning W-D. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 1988; 168: 751–9. 69 Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrene MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84: 9238–42. 70 Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdot AM. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986; 136: 4220–5. 71 Shalaby MR, Palladino MA, Hirabayashi SE, Eessalu TE, Lewis GD, Shepard HM, Aggarwal BB. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukocyte Biol 1987; 41: 196–204. 72 Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile on human septic shock. J Exp Med 1989; 169: 823–32. 73 Horvath CJ, Ferro TJ, Jesmok G, Malik AB. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent on neutrophils. Proc Natl Acad Sci USA 1988; 85: 9219–23. 74 Neilson IR, Neilson KA, Yunis EJ, Rowe MI. Failure of tumor necrosis factor to produce hypotensive shock in the absence of endotoxin. Surgery 1989; 106: 439–43. 75 Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci USA 1988; 85: 607–11. 76 Sun X, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet activating factor. J Clin Invest 1988; 81: 1328–31. 77 Rothstein J, Lint T, Schreiber H. Tumor Necrosis factor/Cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med 1988; 168: 2007–21. 78 van der Poll T, Büller HR, Ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack E, Sauerwein HP, Rosenberg RD, Ten Cate JW Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622–7. 79 Beutler B, Milsark IW, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effects of endotoxin. Science 1985; 229: 869–71. 80 Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the medication of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988; 81: 1925–37. 81 Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental Gram-negative shock. J Infec Dis 1990; 162; 421–7. 82 Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662–4. 83 Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB Jr, Murray CK, Peer GT, Emerson TE Jr, Passey RB, Kuo GC. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circulatory Shock 1990; 30: 279–92. 84 Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627–33. 85 Exley AR, Cohen J, Buurman W, Owen R, Hanson G, Lumley J, Aulakh JM, Bodmer M, Riddell A, Stephens S, Perr M. Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 335: 1275–6. 86 Seckinger P, Isaaz S, Dayer J-M. A human inhibitor of tumor necrosis factor. J Exp Med 1988; 167: 1511–16. 87 Wallach D. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol 1984; 132: 2464–9. 88 Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med 1988; 168: 95–105. 89 Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988; 242: 941–4. 90 Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 1989; 106: 156–62. 91 Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355–7. 92 Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock—mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Amer Rev Resp Dis 1990; 141: 94–7. 93 Calandra T, Baumgartner J-D, Grau GE, Wu M-M, Lambert P-H, Schellekens J, Verhoef J, Glauser MP. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with shock. J Infec Dis 1990; 161: 982–7. 94 Offner F, Philippé J, Vogelaers D, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Leroux-Roels G. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116: 100–5. 95 Young HA, Hardy KJ. Interferon-γ: producer cells, activation stimuli, and molecular genetic regulation. Pharmac Ther 1990; 45: 137–51. 96 Ijzermans JNM, Marquet RL. Interferon-gamma: a review. Immunobiol 1989; 179: 456–73. 97 Murray HW. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Int Med 1988; 108: 595–608. 98 Heremans H, Billiau A. The potential role of interferons and interferon antagonists in inflammatory disease. Drugs 1989; 38: 957–72. 99 Billiau A, Dijkmans R. Interferon-γ: mechanism of action and therapeutical potential. Bioch Pharmacol 1990; 40: 1433–9. 100 Dijkmans R, Billiau A. Interferon-γ: a master key in the immune system. Curr Opinion in Immunol 1988; 1: 269–74. 101 Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991; 5: 171–7. 102 Le J, Lin JX, Hendriksen-Destefano D, Vilcek J. Bacterial lipopolysaccharide-induced interferon-γ: roles of interleukin I and interleukin 2. J Immunol 1986; 136: 4525–30. 103 Matsumura H, Nakano M. Endotoxin-induced interferon-γ production in culture cells derived from BCG-infected C3H/HeJ mice. J Immunol 1988; 140: 494–500. 104 Bancroft GJ, Schreiber RD, Bosma GC, Bosma MJ, Unanue ER. A T cell-independent mechanism of macrophage activation by interferon-γ. J Immunol 1987; 139: 1104–7. 105 Tovey MG, Streuli M, Gresser I, Gugenheim J, Blanchard B, Guymarho J, Vignaux F, Gigou M. Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci USA 1987; 84: 5038–42. 106 Martinez-Maza O, Andersson U, Andersson J, Britton S, de Ley M. Spontaneous production of interferon-γ in adult and newborn humans. J Immunol 1984; 132: 251–5. 107 Gessner A, Drjupin R, Löhler J, Lother H, Lehman-Grube F. IFN-γ production in tissues of mice during acute infection with lymphocytic choriomeningitis virus. J Immunol 1990; 144: 3160–5. 108 Youngner JS, Salvin SB. Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed type hypersensitivity. J Immunol 1973; 111: 1914–23. 109 Mustafa MH, Diener P, Höjeberg B, van der Meide P, Olsson T. T cell immunity and interferon-γ secretion during experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1991; 31: 165–77. 110 Nakagawara A, de Santis NM, Nogueira N, Nathan CF. Lymphokines enhance the capacity of human monocytes to secrete reactive oxygen intermediates. J Clin Invest 1982; 70: 1042–51. 111 Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-β, tumor necrosis factor, or IFN-γ. J Immunol 1988; 141–39: 45–50. 112 Finocchiaro LME, Arzt ES, Fernandez-Castelo S, Criscuolo M, Finkelman S, Nahmod VE. Serotonin and melatonin synthesis in peripheral blood mononuclear cells: Stimulation by Interferon-γ as part of an immunomodulatory pathway. J Interferon Res 1988; 8: 705–16. 113 Littman BH, Dastvan FD, Carlson PL, Sanders KM. Regulation of monocyte/macrophage C2 production and HLA-DR expression by 1L-4 (BSF-1) and IFN-γ. J Immunol 1989; 142: 520–5. 114 Shaw LM, Mercurio AM. Interferon-γ and lipopolysaccharide promote macrophage adherence to basement membrane glycoproteins. J Exp Med 1989; 169: 303–8. 115 Boraschi D, Censini S, Tagliabue A. Interferon-γ reduces macrophage-suppressive activity by inhibiting prostaglandin-E2 release and inducing interleukin-1 production. J Immunol 1984; 133: 764–8. 116 Ripoche J, Mitchell JA, Erdei A, Madin C, Moffatt B, Mokoena T, Gordon S, Sim RB. Interferon-γ induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J Exp Med 1989; 168: 1917–22. 117 Pace JL. Synergistic interactions between IFN-γ and IFN-β in priming murine macrophages for tumor cell killing. J Leukocyte Biol 1988; 44: 514–20. 118 Zuckerman SH, Schreiber RD. Up-regulation of gamma interferon receptors on the human monocytic cell line U937 by 1,25-dihydroxyvitamin D3 and granulocyte-macrophage colony stimulating factor. J Leukocyte Biol 1988; 44: 187–91. 119 Hart PH, Whitty GA, Piccoli DS, Hamilton JA. Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-γ. J Immunol 1988; 141: 1516–21. 120 Aggarwal BB, Eessalu TE, Hass P. Characterization of receptors for human tumor necrosis factor and their regulation by γ-interferon. Nature 1985; 318: 665–7. 121 Brouckaert PGG, Leroux-Roels GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumour activity of recombinant human and murine TNF, alone or in combination with murine IFN-γ, on a syngeneic murine melanoma. Int J Cancer 1986; 38: 763–9. 122 Heremans H, van Damme J, Dillen C, Dijkmans R, Billiau A. Interferon-γ, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 1990; 171: 1853–69. 123 Heinzel FP. The role of IFN-γ in the pathology of experimental endotoxemia. J Immunol 1990; 145: 2920–4. 124 Billiau A, Heremans H, Vandekerckhove F, Dillen C. Anti-interferon-γ antibody protects mice against the generalized Shwartzman reaction. Eur J Immunol 1987; 17: 1851–4. 125 Grau GE, Heremans H, Piguet P-F, Pointaire P, Lambert P-H, Billiau A, Vassalli P. Anti-interferon-γ antibody treatment prevents experimental cerebral malaria and its TNF overproduction. Proc Natl Acad Sci USA 1989; 86: 5572–5. 126 van Snick J. Interleukin-6: an overview. Ann Rev Immunol 1990; 8: 253–78. 127 Richards C, Gauldie J, Baumann H. Cytokine control of acute phase protein expression. Eur Cytokine Network 1991; 2: 89–98. 128 Jiang H, Siegel JN, Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of Clq and inhibition of these reactions by monoclonal antibodies to C-reactive protein and Clq. J Immunol 1991; 146: 2324–30. 129 Zahedi K, Mortensen RF. Macrophage tumoricidal effect induced by human C-reactive protein. Cancer Res 1986; 46: 5077–83. 130 Shephard EG, Anderson R, Beer SM, Jansen Van Rensburg CE, de Beer FC, Neutrophil lysosomal degradation of human CRP: CRP-derived peptides modulate neutrophil function. Clin Exp Immunol 1988; 73: 139–45. 131 Fiedel BA. Platelet response to aggregated C-reactive protein: fibrinogen-dependent and independent signals. Immunology 1988; 63: 169–70. 132 Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced TNF production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143: 3517–23. 133 Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S, Mori K, Imura H. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious freely moving rats. Biochem Biophys Res Commun 1988; 155: 1459–63. 134 Fukata J, Usui T, Naitoh Y, Nakai Y, Imura H. Effects of recombinant human interleukin-1α, -1β, 2 and 6 on ACTH synthesis and release in the mouse pituitary tumour cell line AtT20. J Endocrinol 1989; 122: 33–9. 135 Hack EC, de Groot ER, Felt-Bersma JF, Nuijens JH, Strack Van Schijndel RJM, Eerenberg-Belmer AJM, Thijs LG, Aarden L. Increased plasma levels of interleukin-6 in sepsis. Blood 1990; 74: 1704–10. 136 van Hinsberg VW, van den Berg EA, Fiers W, Dooiewaard G. Tumor necrosis factor induces the production of urokinbase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991–8. 137 Novick D, Engelman H, Leitner O, Wallach D. Soluble cytokine receptors in normal human urine: purification, biological activity and monoclonal antibodies. J Leukocyte Biol 1990; 48–S1;104. 138 Starnes HF, Pearce MK, Tewari A, Yim JH, Zou J-C, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J Immunol 1990; 145: 4185–91. 139 Wolpe SD, Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J 1989; 3: 2565–73. 140 van Damme J. Interleukin-8 and related molecules. In: AW Thomson, ed. The Cytokine Handbook: Immunology and Molecular Biology of Cytokines. Academic Press 1991: 201–14. 141 van Damme J, Decock B, Conings R, Lenaerts JP, Opdenakker G, Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. Eur J Immunol 1989; 19: 1189–94. 142 van Damme J, van Beeumen J, Conings R, Decock B, Billiau A. Purification of monocyte-derived granulocyte chemotactic protein/interleukin-8 reveals N-terminal sequence heterogeneity similar to that of β-thromboglobulin. Eur J Biochem 1989; 181: 337–44. 143 Rampart M, van Damme J, Zonnekeyn L, Herman AG. Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. J Pathol 1989; 135: 21–4. 144 Martich GD, Danner RL, Ceska M, Suffredini F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med 1991; 173: 1021–4. 145 van Zee K, Deforge LE, Fischer E, Marano MA, Kenney JS, Remick DG, Lowry SF, Moldawer LL. IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 1991; 146: 3478–82. Citing Literature Volume21, Issue6December 1991Pages 559-573 ReferencesRelatedInformation
Referência(s)